Rapid Micro Biosystems, Inc. Class A Common Stock

Oct 20, 2026

▼ -0.2%today

Rapid Micro Biosystems to Participate at the PDA Pharmaceutical Microbiology Conference 2026

Rapid Micro Biosystems will sponsor the PDA Pharmaceutical Microbiology Conference 2026 in Washington, D.C. from October 26-28. The event will focus on advancements in microbial quality control, featuring the company's Growth Direct platform. CEO Robert Spignesi emphasized the importance of automation and data integrity in modernizing quality operations.

Sep 4, 2026

▼ -6.9%on this news

Rapid Micro Biosystems to Participate in Upcoming Investor Conferences

Rapid Micro Biosystems (RPID) announced its participation in several upcoming investor conferences, including the Lake Street's Best Ideas Growth Conference and the Sidoti Small-Cap Virtual Conference. The company aims to engage with investors through one-on-one meetings and presentations. Rapid Micro's technology focuses on automating microbial quality control in healthcare manufacturing.

Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results

Rapid Micro Biosystems reported a total revenue of $8.1 million for Q2 2026, reflecting an 11% growth from the previous year. The company achieved a record gross margin of 15% and confirmed its full-year revenue guidance. Despite the positive growth, the company reported a net loss of $12.9 million, consistent with the same period last year.

Aug 4, 2026

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rapid Micro Biosystems announced the grant of 90,000 restricted stock units and a non-qualified stock option for a new employee as part of its Inducement Plan. The grants were approved by independent directors in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price of $2.12 per share and will vest over a period, while the RSUs will vest annually over three years.

Jul 23, 2026

Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026

Rapid Micro Biosystems will announce its second quarter 2026 financial results on August 7, 2026. The announcement will be accompanied by a webcast conference call at 8:30 a.m. ET, allowing stakeholders to engage with the management team. The company specializes in automation solutions for healthcare product manufacturing.

Jun 10, 2026

Rapid Micro Biosystems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rapid Micro Biosystems announced the grant of 60,000 restricted stock units (RSUs) to a new employee as an inducement for employment. This grant, approved under Nasdaq Listing Rule 5635(c)(4), is part of the company's strategy to attract talent. The RSUs will vest over three years, contingent on the employee's continued employment.

May 19, 2026

Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering

Rapid Micro Biosystems has announced the pricing of an underwritten offering of approximately $32 million, which includes shares of Class A common stock and accompanying warrants. The offering aims to raise about $9.8 million initially, with potential additional proceeds of $21.7 million if all warrants are exercised. The offering is expected to close on May 20, 2026, subject to customary conditions.

May 13, 2026

Rapid Micro Biosystems Reports First Quarter 2026 Financial Results

Rapid Micro Biosystems reported a total revenue of $8.0 million for Q1 2026, an 11% increase from the previous year. Product revenue saw a significant rise of 36%, while recurring revenue grew by 28%. Despite these gains, the company experienced a net loss of $14.3 million, up from $11.3 million in Q1 2025. The company reaffirmed its full-year revenue guidance of $37 million to $41 million.

May 6, 2026

Rapid Micro Biosystems to Announce First Quarter 2026 Financial Results on May 13, 2026

Rapid Micro Biosystems, Inc. will announce its first quarter 2026 financial results on May 13, 2026. Following the announcement, the management team will host a webcast conference call to discuss the results. The company specializes in automation solutions for the healthcare industry, particularly in microbial quality control testing.

Mar 12, 2026

▼ -21.8%on this news· ran to -35% by day 1

Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance

Rapid Micro Biosystems reported strong financial performance for Q4 and the full year 2025, with quarterly revenue reaching $11.3 million, marking a 37% growth year-over-year. The company also forecasts continued growth in 2026, estimating total revenue between $37.0 million and $41.0 million, driven by additional Growth Direct system placements. However, despite these positive indicators, there were challenges including a net loss of $12.5 million in the fourth quarter and a decrease in gross margin percentage.

Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Rapid Micro Biosystems, Inc. will announce its fourth quarter and full year 2025 financial results on March 12, 2026. The announcement will be made prior to market opening, followed by a webcast conference call at 8:30 a.m. ET. The company specializes in automation solutions for the healthcare sector, enhancing manufacturing efficiency and safety.

Jan 14, 2026

▲ +21.1%on this news· ran to +45% by day 3

Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue

Rapid Micro Biosystems announced preliminary unaudited revenue results for Q4 and full year 2025, reporting record revenue of approximately $11.3 million for Q4, a 37% increase year-over-year. The full year revenue is expected to reach approximately $33.6 million, reflecting a 20% growth. The company attributes this success to strong demand for its Growth Direct systems and services.

Nov 7, 2025

▲ +12.7%on this news· ran to +51% by day 3

Rapid Micro Biosystems Reports Third Quarter 2025 Financial Results Announces Record Multi-System Customer Order and Raises Full-Year Revenue and System Placement Guidance

Rapid Micro Biosystems has reported its third-quarter financial results for 2025, achieving a total revenue of $7.8 million, an increase of 3% over the same quarter last year. The company experienced significant growth in recurring revenue, up by 32%, and secured its largest multi-system customer order in history. As a result, Rapid Micro has raised its full-year revenue guidance to at least $33 million. However, the company reported a net loss of $11.5 million, slightly exceeding last year's loss, with a gross margin improvement to 9%. Despite the losses, the overall outlook remains positive due to increased demand and innovative product placements.

Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results

Rapid Micro Biosystems reported its second quarter 2025 financial results, revealing a total revenue of $7.3 million, a 10% increase from the previous year. Recurring revenue showed a robust 15% growth, alongside a notable improvement in gross margin at 4%. The company announced a five-year, $45 million term loan facility, which enhances its financial stability and supports future growth initiatives. Despite these positive metrics, the company continues to face challenges, with a net loss of $11.9 million.

Jun 17, 2025

Dear RMB Team Members and Shareholders I am writing on a personal note to let you know that I was recently diagnosed with a treatable form of Lymphoma. The good news is that I have an excellent care team and my doctors h

The CEO of RMB has announced a personal health update, revealing a recent diagnosis of a treatable form of Lymphoma. Despite limiting in-person office time during the expected four-month treatment, the CEO plans to actively manage business operations. The leadership team and board have expressed full support, and the CEO remains optimistic about the company’s continued performance and patient care initiatives.

Rapid Micro Biosystems Reports First Quarter 2025 Financial Results

Rapid Micro Biosystems reported strong first-quarter financial results for 2025, with total revenue reaching $7.2 million, a 28% increase from the previous year. The company announced significant gross margin improvements and record service revenue driven by enhanced validation activities. A distribution agreement with Merck KGaA was also highlighted as a key development. However, the company continues to face challenges, including ongoing net losses.

Mar 4, 2025

rpidxpresentation Rapid Micro Biosystems TD Cowen 45th Annual Health Care Conference Robert Spignesi, President & CEO

At the TD Cowen 45th Annual Health Care Conference, Rapid Micro Biosystems discussed their forward-looking strategies and impressive growth metrics. The company announced a 25% increase in total revenue for FY 2024, achieving a record for quarterly and yearly performance. They highlighted successful collaborations with Merck KGaA (MilliporeSigma) and Lonza, aimed at expanding their products into new markets. Despite these successes, the company acknowledged ongoing financial challenges and emphasized their commitment to achieving positive cash flow by the end of 2027.

Feb 27, 2025

▲ +22.1%on this newsshared move

Rapid Micro Biosystems Announces Global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany

Rapid Micro Biosystems has entered a five-year global distribution and collaboration agreement with Merck KGaA's Life Science business. This partnership grants Merck co-exclusive rights to sell Growth Direct systems, enhancing Rapid Micro's commercial reach in various sectors including pharmaceuticals and food. The agreement aims to explore cost efficiencies and joint product development. It positions both companies to maximize their market offerings and accelerate innovation in manufacturing quality control.

Jan 16, 2025